Cancer cells can activate parallel survival pathways, such as the RAS‐MAPK pathway, to bypass Hippo/YAP inhibition, resulting in drug resistance and decreased effectiveness of single‐agent therapies [148, 151, 176, 177]. This evidence concerns the gene YAP1 and cancer.